Keeping Up With the Treatment Landscape for MDD

CCO Neuroscience Podcast

English - August 01, 2023 15:14 - 28 minutes - 26.4 MB - ★★★★★ - 3 ratings
Courses Education Science Life Sciences movement disorders neuromuscular disorders mood disorders Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Rett Syndrome Tomorrow: Management Options on the Horizon

Next Episode: Defining Alzheimer’s Disease and MCI Management in the Modern Era

The treatment landscape of major depression is increasingly shifting from monoaminergic agents to agents that modulate glutamate and GABA. Healthcare professionals need to stay up to date and educated on these changes in order to discuss the most current treatment options with their patients. In this podcast episode, we interview Dr Anita Clayton, a clinician researcher who has been involved in some of the clinical trials for these novel glutamatergic and GABAergic medications, and ask her key questions about mechanism of action and clinical application. Listeners will come away from this podcast episode more informed and more excited for the future of major depression care.

Presenters:

Anita Clayton, MD
David C. Wilson Professor and Chair
Department of Psychiatry and Neurobehavioral Sciences
Professor of Clinical Obstetrics and Gynecology
University of Virginia School of Medicine
Charlottesville, Virginia

This podcast episode is supported by an educational grant from Sage Therapeutics, Inc. and Biogen.

Link to full program:
https://bit.ly/3YdPMPa